Ichnos Glenmark Innovation (IGI) announced a 75% response rate for its experimental cancer drug ISB 2001 in a Phase 1 clinical trial for relapsed/refractory multiple myeloma. The drug showed good safety results, with no dose-limiting side effects. Full results will be shared at the American Society of Hematology Annual Meeting in December 2024.